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Specific targeting of human caspases using 
designed ankyrin repeat proteins
Abstract: Caspases play important roles in cell death, dif-
ferentiation, and proliferation. Due to their high homology, 
especially of the active site, specific targeting of a partic-
ular caspase using substrate analogues is very difficult. 
Although commercially available small molecules based 
on peptides are lacking high specificity due to overlapping 
cleavage motives between different caspases, they are often 
used as specific tools. We have selected designed ankyrin 
repeat proteins (DARPins) against human caspases 1–9 and 
identified high-affinity binders for the targeted caspases, 
except for caspase 4. Besides previously reported caspase-
specific DARPins, we generated novel DARPins (D1.73, 
D5.15, D6.11, D8.1, D8.4, and D9.2) and confirmed specificity 
for caspases 1, 5, 6, and 8 using a subset of caspase fam-
ily members. In addition, we solved the crystal structure of 
caspase 8 in complex with DARPin D8.4. This binder inter-
acts with non-conserved residues on the large subunit, 
thereby explaining its specificity. Structural analysis of this 
and other previously published crystal structures of cas-
pase/DARPin complexes depicts two general binding areas 
either involving active site forming loops or a surface area 
laterally at the large subunit of the enzyme. Both surface 
areas involve non-conserved surface residues of caspases.
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Introduction
A well-ordered removal of aberrant cells is important in 
multicellular animals to ensure the organism’s cellular 
integrity. Thus, a variety of cell death pathways exist of 
which apoptosis is presumably one of the best-studied 
mechanisms, removing cells in an non-inflammatory 
manner thereby preventing a severe immune response in 
the organism (Taylor et al., 2008). Further, apoptosis plays 
a crucial role in embryonic development and tissue home-
ostasis. Although it is a highly controlled mechanism, its 
misregulation has been associated with severe diseases 
such as cancer or Alzheimer’s disease (Rohn, 2010; Faval-
oro et al., 2012).
Proteases of the caspase family have been identified 
to be the major contributors of apoptosis. Caspases either 
induce (caspases 2, 8, 9, and 10) or execute (caspases 3, 6, 
and 7) the apoptotic signaling (Grütter, 2000). Furthermore, 
caspases 1, 4, 5, and 12 have been related to inflammatory 
pathways. Because all caspases share a high sequence and 
structural homology, specific targeting of one particular 
family member is limited with the contemporary available 
tools. The small peptide substrates or inhibitors lack speci-
ficity due to targeting of the highly conserved active site 
(McStay et al., 2008). Another more promising approach is 
the development of small molecule compounds that bind 
and inhibit caspases 3 and 7 outside the active site pocket, 
although the identified binding site for these compounds 
is conserved between both caspases (Hardy et al., 2004).
To increase a compound’s specificity for a particu-
lar caspase, we used engineered binding proteins that 
provide larger binding interfaces and potentially also 
involve nonconserved residues. For our studies, we 
selected binders using a designed ankyrin repeat protein 
(DARPin) library. DARPins were designed based on repeat 
modules occurring in natural ankyrin proteins and consist 
of an N-terminal capping repeat (N-cap) followed by two 
( = NI2C) or three ( = NI3C) internal and a C-terminal repeat 
(C-cap) (Binz et  al., 2004). Each internal repeat of a 
DARPin harbors six randomized positions resulting in a 
theoretical diversity of 1023 different molecules in assem-
bled DARPin libraries (Binz et al., 2004). These libraries 
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are generally used for binder selections against various 
different targets using ribosome display, an in vitro selec-
tion technique (Hanes and Plückthun, 1997). In addition, 
DARPins have also been successfully selected using phage 
display (Steiner et al., 2008).
Numerous DARPin selections yielding high affinity 
binders for particular target proteins have been reported 
(Amstutz et  al., 2005; Sennhauser et  al., 2007; Stefan 
et al., 2011). In the past, we used DARPin libraries to select 
highly specific inhibitors for caspase 2 (Schweizer et al., 
2007) and caspase 3 (Schroeder et  al., 2013) as well as 
binders for pro- and active caspase 7 that prevent procas-
pase 7 activation (Flütsch et al., 2014).
Here, we describe the general procedure for the selec-
tion of DARPin binders in parallel against the panel of 
human caspase 1–9. The selection led to high-affinity 
binders with the exception of caspase 4. Besides the 
previously reported specific DARPins for caspase 2 (Sch-
weizer et al., 2007), caspase 3 (Schroeder et al., 2013), and 
caspase 7 (Flütsch et  al., 2014), we report novel binders 
for caspases 1, 5, 6, 8, and 9. The binder’s target speci-
ficity for caspases 1, 5, 6, and 8 was evaluated using a 
subset of caspase family members. In addition, we solved 
the first crystal structure of caspase 8 in complex with 
DARPin D8.4 and provide a comparison and analysis of 
the binding interface with the other three previously pub-
lished caspases 2, 3, and 7/DARPin complex interfaces.
Results
Caspase purification
Because the targeted protein’s purity and stability is 
crucial to prevent selection against impurities or degrada-
tion products, we have established purification protocols 
with high reproducibility for caspase 1–9 (Roschitzki-
Voser et al., 2012). The kinetic characterization in combi-
nation with analysis of the oligomeric state determined 
by size exclusion chromatography (SEC) and the purity by 
SDS page ensured that the targeted caspases were prop-
erly folded and active enzymes.
Selection and characterization of 
 caspase-targeted DARPins
DARPin selection was performed using ribosome display 
against caspases 1–9. We modified the selection protocol 
to achieve specificity and introduced pre-panning steps 
against the closest homologues of the targeted caspases 
in the first and third selection rounds (Supplementary 
Figure 1). Furthermore, additional washing has been per-
formed to obtain a slow off rate using an excess of non-
biotinylated targeted caspase after the panning step in the 
second and fourth rounds (Supplementary Figure 1). After 
four rounds of selection, the enriched caspase-targeted 
DARPin libraries have been used to analyze individual 
clones by crude extract ELISA. In general, binders that 
exhibited strong signal to the targeted caspases compared 
with the maltose-binding protein (MBP) control obtained a 
unique identifier (DX.Y), with X indicating the targeted cas-
pases and Y the sequence of discovery. Obtained DARPins 
were sequenced (Supplementary Figure 2), purified, and 
analyzed for complex formation with the targeted caspase 
in solution using SEC (Figure 1A and Supplementary 
Figure 3). Notably, binding of the DARPins can occur to the 
monomeric as well as to the dimeric form of the targeted 
caspase. In addition, SEC traces suggest that binding of 
D1.73 and D8.4 may alter the oligomeric state of the tar-
geted caspase. While first results using ultracentrifugation 
and D8.4 support these findings (data not shown), further 
experiments will be necessary to fully confirm an induced 
change of the oligomeric state upon DARPin binding.
Affinity of binders that displayed unambiguous 
sequencing results and a stable complex on SEC were 
analyzed using surface plasmon resonance (SPR) (e.g., 
caspase 8/D8.4 in Figure 1B). Following this approach, 
we were able to identify DARPins with affinities in the 
low nanomolar range to caspases 1–9 with the exception 
of caspase 4. Measured SPR data for these binders are 
summarized in Figure 1C, where we included the previ-
ously reported values of DARPins with high specificity for 
caspase 2 (Schweizer et  al., 2007), caspase 3 (Schroeder 
et al., 2013), and pro- and active caspase 7 (Flütsch et al., 
2014). Kinetic data have been obtained by fitting the meas-
ured data with the heterogeneous ligand model (Bravman 
et  al., 2006), with exception of D9.2, which exhibited 
a very low signal. Different values of Kd1 and Kd2 can be 
explained by altered accessibility of the two binding 
epitopes most probably originating from the direct coating 
of the caspase molecules via biotin on the sensor chip. 
However, we cannot fully exclude a cooperative binding 
mechanism in case of the caspase 3 binders that exhibit a 
large difference between these two values.
In case of D8.4, the Langmuir model was used to fit 
the data (Figure 1B) obtaining a Kd of 5.2 nm. With the 
exception of D1.73, D8.1, and D8.4, which exhibited high 
χ2 values while curve fitting, binding constants were 
determined by equilibrium analysis. DARPins that were 
selected against caspase 4 exhibited binding in the low 
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millimolar range, three orders of magnitude higher than 
the best binders we have found against the other cas-
pases. An explanation for that observation could be that 
caspase 4 is less stable under selection conditions. Protein 
sequence and biophysical properties of the DARPins listed 
in Figure 1C can be found in Supplementary Table 1.
Caspase specificity of the selected DARPins was deter-
mined using SPR analysis against a representative set of 
caspases (caspases 1, 4, 5, 6, 7, and 8) including members 
of all different pre-panning groups (see Supplementary 
Figure 1). Caspase 3 was excluded due to its lower sta-
bility when coated on the SPR chip, whereas caspases 2 
and 9 were represented by the panning group member 
caspase 8. Although not all caspases were tested in par-
ticular, the chosen array of different caspases is well suit-
able to elucidate the binder’s specificity. It confirms that 
pre-panning during selection leads to not only specificity 
within a panning group (e.g., caspases 1, 4, and 5) but 
also across panning groups with more distantly related 
caspases (e.g., caspases 1, 7, and 8).
With the exception of D9.2, we tested and con-
firmed the binders’ specificity for the targeted caspases. 
Caspase  8 binding specificity was tested using DARPin 
D8.1, which shares a very similar sequence with D8.4 
with only two point mutations (Q26R and V139A, see 
Supplementary Figure 5) suggesting the same binding 
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AR_F8 Casp-2 – – 4.10E-09 – – – –
D3.4S76R Casp-3 1.74E+05 4.20E-03 2.42E-08 1.62E+06 7.45E-04 4.61E-10 6.00E-09
D3.8 Casp-3 1.77E+05 2.49E-03 1.41E-08 2.44E+06 1.11E-04 4.57E-11 3.40E-09
D5.15 Casp-5 1.05E+06 1.01E-02 1.00E-08 2.85E+05 5.97E-04 2.10E-09 1.10E-08
D6.11 Casp-6 6.05E+05 1.05E-02 2.13E-08 1.55E+05 9.66E-04 6.23E-09 3.37E-08
D7.18 Casp-7 1.73E+05 1.31E-02 7.60E-08 1.08E+04 2.11E-04 1.96E-08 1.44E-07
D7.43 Casp-7 4.44E+04 9.97E-04 2.30E-08 6.65E+05 1.77E-02 2.70E-08 2.47E-08
D8.1 Casp-8 6.00E+04 1.96E-03 3.27E-08 – – – –
D8.4 Casp-8 1.80E+05 9.31E-04 5.20E-09 – – – –
D9.2 Casp-9
(1)
(2)
(2)
(3)
(3)
– – – – – – 1.80E-08
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Figure 1 Binding characterization of selected DARPins.
(A) Selected DARPins were analyzed on SEC for the formation of a stable complex in solution (see also Supplementary Figure 3). Caspase 8 
exhibits a monomer-dimer equilibrium [marked with (m) and (d), respectively]. D8.4 binds to both the monomer and the dimeric forms 
of caspase 8 and elutes at earlier retention volume as a protein complex (solid lines, complex peak marked with (C) and (Dp) for DARPin 
excess). Calibration curve (right ordinate) was made using aldolase (158 kDa), conalbumin (75 kDa), ovalbumin (43 kDa), carbonic 
anhydrase (29 kDa), ribonuclease A (13.7 kDa), and aprotinin (6.5 kDa). Furthermore, (B) binding affinities were determined using SPR. 
(C) Binding affinities and kinetic constants of selected DARPins. Binders with two indicated kinetic constants were determined using the 
heterogeneous ligand model (Bravman et al., 2006). D8.1 and D8.4 kinetic data were determined using the Langmuir model. The equilib-
rium KD determination for D1.73, D8.1, and D8.4 resulted in high χ2 values and are therefore excluded. Previously reported DARPins are 
indicated with a gray background, and references are given with numbers: (1) Schweizer et al. (2007), (2) Schroeder et al. (2013), (3) Flütsch 
et al. (2014).
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interaction. Binding specificities for AR_F2, D3.4S76R, 
D3.8, D7.18, and D7.43 were reported previously (Schweizer 
et al., 2007; Schroeder et al., 2013; Flütsch et al., 2014).
Crystal structure of caspase 8 in complex 
with D8.4
To obtain a better understanding of the binding interac-
tions between a selected DARPin and the targeted caspase, 
we have crystallized caspase 8 in complex with DARPin 
D8.4 and determined the structure at 1.8 Å resolution. 
Structure determination details and refinement statistics 
are listed in Supplementary Table 2. Crystals grew under 
acidic conditions at pH 4.9, indicating that the protein inter-
action remains intact even at low pH. This was also tested 
in ELISA format (data not shown) and showed that binding 
still occurs at acidic pH values, although a lower signal 
compared with neutral pH suggests a weakened binding 
affinity. The asymmetric unit contains a caspase 8 dimer 
consisting of two small and two large subunits, two bound 
inhibitor molecules Ac-IETD-CHO, and two bound DARPins 
(Figure 2A). The binding epitope is localized on the side of 
the large subunit of the enzyme and primarily involves resi-
dues of α-helix α2 as well as β-strand β2 (Figure 2B).
In total, 25 caspase 8 residues are involved in 
binding to 31 residues of the DARPin spanning a binding 
interface of 938 Å2. Sixteen hydrogen bonds and 7 salt 
bridges surround a hydrophobic core, which is formed 
by amino acids Phe-56, Leu-86, Leu-89, Phe-90, and 
Phe-123 of the DARPin and Gln-291, Ile-295, and Ile-298 
of caspase 8 (Figure 2B). Remarkably, besides the 16 
non-randomized residues that are involved in binding, 
D8.4 possesses two unintended framework mutations 
(Arg-26 and Arg-85, see Supplementary Figure 5), which 
play a role in hydrogen bonding to caspase 8 (marked in 
Figure 2B, left).
As intended, the specificity of D8.4 for caspase 8 is 
achieved by targeting of non-conserved residues. Espe-
cially the hydrophobic interaction provided by Ile-298 
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Figure 2 Caspase 8 in complex with DARPin D8.4.
(A) Standard view of caspase 8 (small subunit in light gray, large subunit in dark gray, Ac-IETD-CHO inhibitor in orange) in complex with 
DARPin D8.4 (N- and C-cap in dark blue, internal repeats are light blue). The DARPin binds lateral at the large subunit of the enzyme. (B) 
Close-up view of the caspase 8/DARPin D8.4 binding interface displaying the major interactions between the DARPin and α-helix α2 of 
caspase 8 (left) and the interactions of D8.4 with β-strand β2 of caspase 8 (right). Important residues are labeled in blue (DARPin) and gray 
(caspase 8). See also Supplementary Figure 5 for a list of interacting residues.
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(Figure 2B, right) is not conserved among the apoptotic 
caspases, which harbor a larger and more hydrophilic 
residue at this position (Supplementary Figure 5). Besides 
that, only Thr-288 at the beginning of α-helix α1 was iden-
tified as highly conserved. Therefore, our crystal structure 
not only provides insights into the binding interface but 
also elucidates the specificity of the selected DARPin. In 
addition, it confirms our chosen selection procedure with 
the additional pre-panning steps against homologues cas-
pases. A structural alignment of our caspase 8/DARPin-8.4 
structure with the high-resolution structure of the same 
enzyme (1QTN; Watt et al., 1999) results in a very low root 
mean square deviation of about 0.7 Å, indicating no or 
only minor differences between the two structures. While 
they show no structural differences in the overall fold and 
the active site, several side chains in the caspase/DARPin 
interface adopt different conformations (e.g., Glu-290, Glu-
294, Ile-298) due to the presence of the DARPin D8.4.
DARPin binding interfaces on human 
caspases
With the previously described crystal structures of cas-
pases in complex with specific DARPins (Schweizer et al., 
2007; Schroeder et al., 2013; Flütsch et al., 2014), we were 
able to compare the different DARPin epitopes for each 
particular caspase (Figure 3).
Based on the caspase standard view, where the five 
main parallel β-strands (β1–β5) of a caspase protomer are 
aligned with their C-termini pointing upwards, caspase 
2-specific DARPin AR_F8 (Figure 3A; Schweizer et  al., 
2007) binds apical at the backside of loop 4 (also known 
as loop 381; Fuentes-Prior and Salvesen, 2004), which is 
involved in the formation of the active site cleft. Because 
this loop is not highly conserved among other caspases, 
it explains the high specificity of DARPin AR_F8 for 
caspase 2. The binding area of 799 Å2 includes a hydropho-
bic core, six hydrogen bonds, and nine salt bridges. AR_F8 
binding at the backside of loop 4 leads to a loop shift of 1 Å 
and opens the active site cleft (Schweizer et al., 2007). This 
finally results in a displacement of the active site cysteine 
(Cys-155) and structurally elucidates the allosteric mode of 
inhibition.
Although DARPin D3.4S76R binds in a similar way 
apical to caspase 3 (Figure 3B; Schroeder et  al., 2013) at 
the active site forming loops, the epitope is only partially 
overlapping with that of caspases 2 and AR_F8. D3.4S76R 
binds directly into the active site pocket of caspases 3 and 
only interacts with the tip of loop 4. Its high specificity is 
achieved by the formation of a salt bridge between Lys-56 
and the Asp-253 of caspase 3. Interestingly, the interact-
ing DARPin residue Asp-45 occupies the S4 pocket of the 
enzyme, as it can be observed in binding of peptide sub-
strates. In addition, Ile-78 of the DARPin keeps Tyr-204 of 
caspase 3 in a conformation that blocks the S2 binding 
pocket. Overall, the binding of D3.4S76R to caspase 3 pre-
vents substrate entrance to the active site pocket and mimics 
an interaction seen for caspase 3 with its natural inhibitor 
XIAP (Schroeder et al., 2013). Enzyme kinetic analysis has 
classified D3.4S76R as a purely competitive inhibitor.
Besides the apical binding sites of AR_F8 and 
D3.4S76R, another favored caspase/DARPin epitope could 
be identified laterally at the large subunit of the peptidase. 
In addition to the above-described DARPin D8.4 that binds 
sideways at the large subunit (p20) primarily to residues 
of α-helix α2 (Figure 3D), DARPins that have been selected 
against caspase 7 bind at a similar epitope (Flütsch et al., 
2014). For instance, the crystal structure of caspase 7 
in complex with DARPin D7.18 (Figure 3C) unraveled a 
binding interface of 672 Å2 that is predominantly formed by 
residues located on β-strand β2. In particular, two DARPin 
tryptophans (Trp-46 and Trp-78) are deeply buried in a 
hydrophobic pocket shaped by non-conserved residues of 
caspase 7. Because this hydrophobic pocket is obstructed 
in other homologues, these two tryptophans are the major 
contributors for the high specificity of DARPin D7.18. 
Although there is another caspase 7/DARPin complex 
structure available (pdb: 4JB8; Seeger et  al., 2013) with 
DARPin C7_16 binding laterally at the large subunit of cas-
pases 7, we excluded this protein complex in our structural 
analysis. This DARPin has been selected without addi-
tional pre-panning steps and thus may lack specificity.
More interestingly, D7.43 and D7.18 also bind to pro 
caspase 7, thus preventing a successful activation (Flütsch 
et al., 2014). D8.4 with a lateral but different binding epitope 
would suggest a potential effect on the activation mecha-
nism in analogy to the caspase 7 DARPins. However, the 
activation mechanism of caspase 8 is different compared 
with the caspase-mediated cleavage of procaspase  7. It 
occurs via autocatalytic processing after proximity-induced 
oligomerization (Salvesen and Dixit, 1999) and therefore is 
dependent on the oligomeric state of caspase 8. Complex 
formation on SEC (Figure 1A) and first ultracentrifugation 
experiments (data not shown) demonstrate that D8.4 can 
bind to the monomer as well as to the dimer of caspase 8 
in vitro. Whether binding in a cellular environment to the 
full procaspase 8 with its two N-terminal death effector 
domains occurs and modulates caspase 8 activation has 
not been further analyzed and remains unknown.
All the complex structures display binding of one 
selected DARPin to one caspase protomer; thus, every 
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Figure 3 Caspase-specific DARPins: complex structure overview.
Currently available caspase structures in complex with specific DARPins are shown in standard view and rotated (90° around the y-axes). 
Interacting residues on the caspase surface are colored according to the color of the binding DARPin. (A) AR_F8 binds caspase 2 from the 
backside of loop 4. (B) D3.4S76R blocks the active site cleft of caspase 3. (C) D7.18 binds at the large subunit (p20) of caspase 7. (D) A 
similar epitope can be observed for caspase 8-specific DARPin D8.4. (E) Superposition of all DARPins on caspase 8 visualizes the different 
epitopes. See also Supplementary Figure 6 for a sequence alignment of all caspases and the interacting caspase residues.
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caspase dimer has two DARPins bound. A superposition of 
all DARPins on caspase 8 shows the particular difference 
between the binding interfaces and emphasizes similari-
ties (Figure 3E). While the apical epitope of DARPin AR_F8 
is located at the backside of loop 4, D3.4S76R binds inside 
the active site cleft and completely blocks an entrance of 
substrate. The lateral binding at the large subunit is less 
distinct. DARPin D7.18 and D8.4 share a similar binding 
area on the caspase surface, but their position is slightly 
tilted by an angle of 30°. Notably, the N-terminus of 
all DARPins is oriented to the backside in the standard 
caspase representation resulting in a ‘dorsal to ventral’ 
DARPin orientation.
Comparison of these DARPin epitopes on the caspase 
surface suggests that binding in specific manner is more 
likely if it occurred at the outer rim of the enzyme rather 
than centrally located close to the dimer interface of two 
caspase protomers. However, we cannot exclude that this 
finding is experimentally influenced by the immobilization 
of the caspase molecule during the selection procedure. 
Random chemical biotinylation may orient the enzyme in 
a particular direction that binding to the outer rim is more 
likely. Besides that, it has been shown that the central cavity 
formed by two caspase protomers is conserved between 
caspases 3 and 7 (Hardy et  al., 2004), suggesting a less 
favored epitope for high caspase specificity in close prox-
imity to the cavity. In addition, exosite studies on caspase 7 
revealed that surface residues located at the large subunit 
influence the cleavage efficiency for particular substrates 
(Boucher et  al., 2012). For example, a caspase 7 mutant 
(K69L) exhibited reduced processing of the Hsp90 co-chap-
erone p23. More interestingly, Lys-69 is also involved in 
binding to DARPin D7.18, is not conserved in other caspases 
(see Supplementary Figure 6) and the caspase 8 homologue 
residue (Tyr-235) also contributes to DARPin D8.4 binding. 
Although very preliminary, this finding indicates that 
the non-conserved caspase residues involved in DARPin 
binding might also be of importance in providing specific 
binding interactions to certain caspase substrates.
Discussion
Using the here-described DARPin selection procedure 
including pre-panning steps against close homologues, we 
obtained new binders against five members of the human 
caspase family. We characterized these novel DARPins for 
caspases 1, 5, 6, 8, and 9 and included data of the previ-
ously reported specific binders for caspases 2, 3, and 
7 (Schweizer et  al., 2007; Schroeder et  al., 2013; Flütsch 
et al., 2014). Caspase specificity of the new DARPins D1.73, 
D5.15, D.6.11, and D8.1 was tested using a subset of caspase 
family members (caspases 1, 4, 5, 6, 7, and 8). Although 
our results suggest high target specificity, binding of the 
DARPins to caspases 2, 3, and 9 was not tested.
The crystal structure of caspase 8 in complex with 
DARPin D8.4 provides insights into the binding mode 
of this high affine binder. D8.4 binds lateral to the large 
p20 subunit of the enzyme and does not interfere with 
the active site of the enzyme. The binding interface of 
caspase  8 involves a hydrophobic patch consisting of 
several non-conserved caspase residues and thus explains 
its specificity. Although the previously reported DARPins 
for caspases 2, 3, and 7 are binders with inhibitory func-
tion (Schweizer et al., 2007; Schroeder et al., 2013; Flütsch 
et  al., 2014), the here newly reported DARPins do not 
prevent cleavage of small peptide substrates in vitro. If 
these binders can interact with the targeted procaspases 
and interfere with the activation process has not been 
tested and needs to be addressed in future experiments.
A structural comparison of all available caspase/
DARPin complexes reveals two distinct binding regions 
on the caspase surface. One is located apical close or at 
the active site. Here the DARPins interact with active site 
forming loops or with residues in the active site and thereby 
inhibit the enzyme either allosterically or competitively. 
The other favored region is found laterally at the large 
subunit of the peptidase and involves α-helix α1 and α2 as 
well as β-strand β2. With this study, we show that specific 
DARPins can be selected against a particular member of a 
highly homologous protein family sharing a high sequence 
identity. Thus, these DARPins provide a molecular toolbox 
for functional and structural investigations either in vitro or 
in cell-based assays using mammalian expression vectors.
Materials and methods
All reagents were bought from Sigma/Fluka if not stated otherwise. 
Sequencing was performed at Microsynth (Balgach, Switzerland).
Caspase purification and biotinylation
Caspase 1–9 have been purified as described previously (Roschitzki-
Voser et al., 2012). Ribosome display selection and ELISA experi-
ments were performed using chemically biotinylated caspases 
(EZ-Link Sulfo-NHS-LC-LC-Biotin, 21338; Pierce Biotechnology, 
Rockford, IL, USA). After purification, 1  ml of caspase (10 μm) in 
phosphate buffer saline (PBS), pH 7.3, or 50 mm HEPES, pH 7.5, 
containing 150 mm NaCl was incubated with a molar excess (7 × , 
70 μm) of biotin on ice for 30 min. The reaction was quenched by 
adding 5 m Tris pH 7.5 (10 μl). Biotinylated proteins were purified by 
SEC using a Superdex 200 10/300 GL (GE Healthcare, Piscataway, 
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NJ, USA) equilibrated in PBS at 4°C. Fractions containing bioti-
nylated caspases were pooled, frozen in liquid nitrogen after add-
ing sucrose (10%), and stored at -80°C in small aliquots.
DARPin selection by ribosome display
Cloning and amplification of a DARPin library has been described 
previously (Binz et  al., 2003) and a library containing NI3C and 
NI2C DARPins was used for selections by ribosome display (Hanes 
and Plückthun, 1997; Zahnd et  al., 2007). The selection procedure 
was slightly modified with focus on specificity and low koff rates 
(see Supplementary Figure 1). To prevent unspecific binding to ran-
dom proteins, each round included a pre-panning step for MBP 
(coated 22 nm). In addition, two of the most homologues caspases 
were included in pre-panning steps (coated 22 nm) in rounds 1 and 3. 
koff maturation was done by adding a 100- and 500-fold excess of unbioti-
nylated caspase for 5 or 10 min in rounds 2 and 4, respectively. Unbound 
DARPin/ribosome complexes were washed after each round with 
increasing stringency (Supplementary Figure 1). The enriched library 
was cloned after 4 selection rounds into a pQE30 vector and transfected 
to XL1-Blue Escherichia coli cells (Stratagene, La Jolla, CA, USA).
Crude extract ELISA
Single E. coli colonies, each expressing one selected DARPins, were 
picked and inoculated in 900 μl auto-inducing media (Studier, 2005) 
using 96-well plates (Abgene by Fisher Scientific, Wohlen, Switzer-
land). Cells grew over night at 37°C; 200 μl of each well were then 
transferred to a 96-well plate (Nunc by Thermo Fisher Scientific, 
Waltham, MA, USA) for plasmid preparation, and 700 μl were har-
vested by centrifugation. Cells were lysed using B-PER II (50 μl, 78260; 
Pierce Biotechnology, Rockford, IL, USA) per well (30 min, shaking at 
room temperature). Lysis buffer was neutralized with PBS (950 μl) 
and cell debris was removed by centrifugation (20 min, 4500 rpm at 
4°C). A 20-μl supernatant were transferred to 384 well ELISA plates 
(Nunc by Thermo Fisher Scientific, Waltham, MA, USA), which were 
prepared in advance with either immobilized MBP or targeted cas-
pase. For immobilization, plates were coated using NeutrAvidin solu-
tion (20 μl at 22 nm, 31000; Pierce Biotechnology, Rockford, IL, USA), 
followed by incubation of biotinylated proteins and extensive wash-
ing. Cell lysate supernatants containing the expressed DARPin were 
incubated for 1  h at room temperature. After three washing cycles 
(PBS), each well was incubated with mouse anti-RGS-H4 antibody 
(1:2000 in PBS+1% bovine serum albumin, 34650; Qiagen, Boston, 
MA, USA). After washing, the secondary antibody (goat α-mouse IgG 
alkaline phosphatase conjugate from Sigma; A3562) was incubated. 
After four washing cycles, the substrate (3 mm di-sodium 4-nitro-
phenyl phosphate in 50 mm NaHCO3, 50 mm MgCl2) was added and 
OD405 nm was measured using a multiwell plate reader (Tecan Infinity 
M1000, Tecan, Männedorf, Switzerland). DARPins exhibited strong 
signals ( > 5-fold vs. MBP control) were sequenced.
Expression and purification of DARPins
DARPins were expressed in auto-inducing media (Studier, 2005) 
overnight or in 2YT (3 h at 37°C) after the induction with isopropyl 
β-d-1-thiogalactopyranoside (0.5 mm, IPTG) at an OD600 nm between 0.6 
and 1. Cells were harvested (6000 rpm, 5 min, 4°C; Biofuge primo R, 
Heraeus, Hanau, Germany) and lysed by ultrasonification. DARPin 
purification was performed by immobilized metal-affinity chroma-
tography (gravity columns, 0.5  ml Ni2+-NTA agarose beads, 30210; 
Qiagen, Boston, MA, USA). DARPins were eluted in PBS, 200  mm 
imidazole, pH 7.4. Imidazole was removed using a PD-10 desalting 
column (17-0435-01; GE Healthcare, Piscataway, NJ, USA). For storage 
at 4°C, 0.05% sodium azide (NaN3) was added, whereas 20% glycerol 
was used for storage at -20°C.
Complex formation on SEC
Purified caspases were incubated with a 2-fold molar excess of 
selected DARPins. Protein solutions were applied on SEC using a 
Superdex 200 5/150 GL column (GE Healthcare, Piscataway, NJ, 
USA) equilibrated in 50 mm Tris, 150 mm NaCl, pH 7.5. Absorption at 
280  nm was recorded and analyzed in Prism (Version 5, GraphPad 
Software, La Jolla, CA, USA).
SPR analysis
SPR experiments were performed using a Proteon XPR36 (Bio-Rad Lab-
oratories, Hercules, CA, USA) and an NLC sensor chip. Sterile filtered 
PBS, pH 7.3, 0.005% Tween 20, was the standard buffer for all coating and 
kinetic measurements. Approximately 1000 RU of biotinylated caspases 
(5 nm) were coated on the chip at 30 μl/min. Dilution series of DARPin 
analytes were prepared prior to the experiment in 96-well plates and 
sealed to prevent evaporation or contamination. At least eight differ-
ent concentrations (0–500 nm) starting with the lowest concentration 
were measured at 20°C. Due to the heterogeneity of the system, the 
chip surface was not regenerated between different analyte concen-
tration but dissociation time could be prolonged up to 30 min. In 
general, experiments were performed at flow rates of 100 μl/min with 
5-min association phases and 20 min dissociation phases. Recorded 
data were processed and evaluated using ProteOn Manager 2.1.1 (Bio-
Rad Laboratories, Hercules, CA, USA). Binding kinetics and affinities 
were determined by equilibrium analysis or curve fitting (Bravman 
et al., 2006).
Crystallization of caspase 8 in complex with DARPin 
D8.4
Caspase 8 was incubated with a 2-fold molar excess of DARPin D8.4 
(10 min on ice). The formed complex was separated using a Superdex 
200 10/300 GL column (GE Healthcare, Piscataway, NJ, USA), 20 mm 
Tris, pH 7.5 (4°C), 20 mm NaCl. Fractions containing the dimeric cas-
pase 8/D8.4 complex were pooled and concentrated (15–21 mg/ml) 
using an Amicon Ultra centrifugation device (10 kDa MWCO, EMD Mil-
ipore, Darmstadt, Germany). Prior to crystallization, the protein solu-
tion was incubated with a peptide aldehyde inhibitor Ac-IETD-CHO 
(two inhibitors per active site). Crystals were grown at room tempera-
ture using sitting-drop vapor-diffusion method (100 mm citric acid, 
pH 4.9, 200 mm Li2SO4, and 22.4% PEG 4000). For cryoprotection, the 
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crystals were equilibrated in reservoir buffer containing ethylene gly-
col (10%–15%) and flash frozen in a nitrogen stream at -170°C.
X-ray diffraction, data collection, and structure  
determination
Diffraction data were collected at the Swiss Light Source (SLS, X06SA 
beamline) on a Pilatus 6M fast readout pixel detector. XDS (Kabsch, 
2010) was used for data processing. The crystal structure was solved 
by molecular replacement using PHASER (McCoy et  al., 2007) and 
the structure of caspase 8 (1QDU) (Blanchard et  al., 1999) and a 
NI3C-DARPin (2QYJ) (Merz et  al., 2008) as search model. Structure 
refinement was performed with REFMAC 5.5.01.09 (Murshudov et al., 
1997) and binding interface analysis was done using the EPPIC server 
(Duarte et al., 2012) (www.eppic-web.org). Structure figures were pre-
pared in PyMOL (http://www.pymol.org).
Accession numbers
Atomic coordinates and structure factors of caspase 8/D8.4 were 
deposited in the Protein Data Bank (2Y1L).
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